M
ORKA

Murchinson’s Oruka Therapeutics ORKA Stock Holding History

Murchinson’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,216
Closed -$103K – 105
2023
Q2 		$103K Sell
4,216
-184
-4% -$4.53K 0.01% 49
2023
Q1 		$101K Buy
4,400
+184
+4% +$4.85K 0.01% 39
2022
Q4 		$120K Buy
+4,216
New +$108K 0.02% 38
2022
Q3 		– Sell
-4,216
Closed -$126K – 95
2022
Q2 		$126K Buy
+4,216
New +$119K 0.02% 61

Other funds holding ORKA

WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Murchinson's ORKA Position: Q3 2023 in Review

Murchinson sold out of Oruka Therapeutics (ORKA) in Q3 2023, closing a stake of 4,216 shares — an estimated $103K sold.

Murchinson first reported a position in ORKA in Q2 2022 and held it in 4 quarters. The position peaked at $126K in Q2 2022. 21 funds tracked by Wall St. Rank hold ORKA as of Q3 2023.

  • Murchinson reported no remaining Oruka Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Murchinson sold 4,216 Oruka Therapeutics shares in Q3 2023, an estimated $103K.
  • Murchinson first reported a position in Oruka Therapeutics in Q2 2022 and held it in 4 quarters.
  • Murchinson's Oruka Therapeutics position peaked at $126K in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2023.

Based on Murchinson's 13F filing for Q3 2023, filed 14 Nov 2023.